InspireMD Q4 revenue rises 62%, beats estimates
Overview
Carotid stent developer's Q4 revenue grew 62% yr/yr, beating analyst expectations
Q4 operating loss and net loss were lower than analysts' forecasts
Revenue growth driven by U.S. launch of CGuard Prime and rising international demand
Outlook
InspireMD expects 2026 revenue between $13 mln and $15 mln, up 45%-65% over 2025
Company sees continued momentum in U.S. and international demand for CGuard platform
Approval for TCAR indication could expand U.S. market opportunity, pending FDA decision
Result Drivers
U.S. SALES - U.S. revenue rose 74% sequentially, driven by CGuard Prime
INTERNATIONAL DEMAND - International revenue rose due to increased penetration of key markets with CGuard
HIGHER OPERATING EXPENSES - Operating expenses increased due to greater headcount and investment to support U.S. commercial launch
Company press release: ID:nGNXb9PBxm
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $3.15 mln | $2.63 mln (3 Analysts) |
Q4 Net Income | Beat | -$11.76 mln | -$15.003 mln (3 Analysts) |
Q4 Income From Operations | Beat | -$12.08 mln | -$15.14 mln (3 Analysts) |
Q4 Basic EPS |
| -$0.14 |
|
Q4 Gross Profit |
| $1.18 mln |
|
Q4 Operating Expenses |
| $13.26 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for InspireMD Inc is $5.00, about 179.3% above its March 17 closing price of $1.79
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
